STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals

In April 2026, Nora Volkow and Xu reviewed reports of lower rates of alcohol-related events, reduced opioid overdose risk, and associations extending to nicotine, cocaine, cannabis, and other substances
In todays article, we discuss the importance of hydration (especially with clear fluids) in medical weight loss with GLP-1 prescriptions like Ozempic, Wegovy, Mounjaro, and more
HOMA- (Homeostasis Model Assessment) and HOMA-IR (Insulin Resistance) were calculated on the day 10 of the study